Vactosertib With Nal-IRI/FL in Metastatic Pancreatic Ductal Adenocarcinoma.
Status:
Not yet recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
To determine recommended phase 2 dose and to evaluate the safety of vactosertib in
combination with nal-IRI/FL in patients with metastatic pancreatic ductal adenocarcinoma
(PDAC) who have failed first-line gemcitabine and nab-paclitaxel